• ALVEGA-3 capsules

    R289,00 incl VAT
    FLORA FORCE® ALVEGA-3 capsules contain vegan friendly, non-GMO, high quality purified DHA Omega-3 oil, sourced straight from the origin - marine algae. Because it’s high in DHA, this vegan friendly soft gel capsule is essential to a healthy brain and nervous system. FLORA FORCE® Alvega-3 capsules are 100% free from:
    • Added sugar or lactose
    • Artificial colourants or flavourants
  • ALVEGA-3™ Triple Pack

    R578,00 incl VAT
    FLORA FORCE® ALVEGA-3 capsules contain vegan friendly, non-GMO, high quality purified DHA Omega-3 oil, sourced straight from the origin - marine algae. Because it’s high in DHA, this vegan friendly soft gel capsule is essential to a healthy brain and nervous system. FLORA FORCE® Alvega-3 capsules are 100% free from:
    • Added sugar or lactose
    • Artificial colourants or flavourants
  • Anti-Flu™ drops

    R127,71 incl VAT
    Relieves symptoms of colds and flu, congestion, fever, inflammation, headaches and swollen glands. Supports the immune system, helping to overcome infections and inflammation. The action is anti-inflammatory, decongestive, analgesic and immune stimulatory. The anti-hyaluronidase action inhibits the virus’s ability to enter cells. The action on the circulation stimulates removal of toxins and reduces congestion. 50ml herbal tinctures. Ingredients: Each 3ml contains the equivalent of: 66mg Sambucus nigra, 6mg Zingiber officinalis, 96mg Eupatorium perfoliatum, 33mg Phytolacca decandra, 33mg Echinacea spp., 51mg Fillipendula ulmaria, 15mg Capsicum minimum.
  • Improves function of urinary system – kidneys and bladder. Acts as bladder anti-septic. Relieves irritation and inflammation of bladder. Can be used for BPH and auto-immune kidney disease. Aids diuresis in persons with kidney conditions accompanied by oedema. Action of constituents is anti-microbial, anti-inflammatory, anti-septic; inhibits micro-organism growth in the urinary system and prevents urine retention. 50ml herbal tinctures. Ingredients: Each 3ml contains the equivalent of: 78mg Agathosma betulina, 34mg Arctostaphyllos uva-ursi, 27mg Achillea millefolium, 27mg Melissa officinalis, 27mg Avena sativa, 30mg Echinacea spp., 27mg Vaccinium myrtillus, 25mg Equisetum arvense, 25mg Plantago major.
  • Reduces inflammation, itching and swelling associated with thrush and symptoms associated with fungal infections. Lessens recurrence of fungal infections. 50ml herbal tinctures. Ingredients: Each 3ml contains the equivalent of: Hydrastis canadensis 60mg; Agathosma betulina 56mg; Hamamelis virginiana 21mg; Tabebuia impetiginosus 45mg; Commiphora mol-mol 21mg; Juniperus communis 10mg; Echinacea spp.; Baptisia tinctoria 21mg; Olea europea 21mg.
  • Anti-ageing properties prevent degenerative disease by reducing free radicals. The anti-oxidant properties of the catechins in green tea reduce free radicals and have a detoxifying action. The flavonoids have an anti-inflammatory and protective action against cardiovascular diseases and strengthen blood vessels. Used in weight management. 400mg, 90 capsules.
  • Circulation Formula™

    R127,21 incl VAT

    Flora Force Circulation Formula Package Insert

    Scheduling status: C0 Proprietary name (and dosage form): Flora Force Circulation Formula. Composition: Each 3ml of Circulation contains 120mg Ginkgo biloba EQUIV, 30mg Achillea millefolium EQUIV, 24mg Melissa officinalis EQUIV, 24mg Mentha piperita EQUIV, Arnica montana 3cH, 12mg Viscum album EQUIV, 9mg Hypericum perforatum EQUIV, 12mg Ruscus aculeatus EQUIV, 15mg Capsicum minimum EQUIV, 15mg Astragalus membranaceus EQUIV, 15mg Vaccinium myrtillus EQUIV, Alc 60% v/v. Pharmacological classification: Category D Western Herbal Medicine Pharmacological action: 7.6 Vascular medicines, Others Indications: Herbal medicine for the support of the circulatory system. Contra-indications: Do not use during pregnancy. Circulation formula contains Melissa officinalis and should not be use by persons with low thyroid activity due to its anti-thyrotropic effect. Arnica montana homeopathic 3cH may have a possible blood thinning action; avoid Circulation formula for 3 days before surgery. Circulation formula is contraindicated for persons on SSRI drugs and anti-coagulant drugs. Warnings: Not to be used by persons on anti-coagulant medication. Not to be used during pregnancy. Do not use continuously without consulting a healthcare practitioner. Arnica monta: homeopathic 3cH may have a possible blood thinning action avoid Circulation formula for 3 days before surgery. Drug Interaction: The individual constituent interactions from literature are: Ginkgo: Anti-coagulant medication, warfarin, Ticlopidine and Aspirin. Mentha piperita:  interferes with action of propulsid and closure of oesophageal sphincter Hypericum perforatum: persons on SSRI drugs should not take Circulation formula. Capsicum minimum the active ingredient capsaicin is an ACE inhibitor: There is a theoretical concern because capsaicin depletes substance P. It is a very low risk level however the Patient should be monitored. Theophylline: Cayenne increase absorption and bio-availability as per clinical study.  Risk level is low patient should be monitored. Vaccinium myrtillus: Warfarin. Anti-platelet activity has been observed with high doses of herb. Pregnancy and Lactation: Not do be used during pregnancy and breastfeeding. Dosage and directions for use: Take 20 drops in 25ml water three times daily, or as prescribed. Side-effects and special precautions: Not to be used by persons on anti-coagulant medication. Hypersensitivity with known plant allergy. Known symptoms of over dosage and particulars of its treatment: None known. Consult a practitioner or nearest poison care centre. Identification: Pale to bright yellow liquid, sharp in smell and bitter, sharp in taste. Presentation: 50ml amber glass dropper bottle with white tamper evident screw cap within a product box. 500ml amber glass bottle with white tamper evident screw cap. Storage instructions: Store in a cool dark place below 25ºC. KEEP OUT OF REACH OF CHILDREN. Registration number: To be allocated. Applicant: Flora Force Health Products (Pty) Ltd., PO Box 426, Rondebosch, 7701, Cape Town Date of publication: 17/11/2014
  • DISCONTINUED Herbal anti-septic and anti-inflammatory. Relieves flatulence, wind, colic and nausea. Clove has a carminative action, improving digestion and relieving indigestion, inflammation and pain of peptic ulcers. Use together with Slippery elm in case of ulcers. Can be used together with Juglans nigra and Artemisia absinthinum to eliminate parasites in the egg stage. Used for treatment of malaria, TB and cholera in tropical areas. 500mg, 80 capsules.
  • Dandelion capsules

    R129,23 incl VAT
    FLORA FORCE® DANDELION capsules traditionally used to support the body’s elimination functions. Vege caps. Free from additives, sugar and lactose.

    PATIENT INFORMATION LEAFLET

    Information currently undergoing revision, please return within the next 24 to 48 hours.
    Information currently undergoing revision, please return within the next 24 to 48 hours.

    Herb Library

    Explore our Herb Library for additional information on traditional uses of herbs.

    Related blog articles

    Read more about dandelion in our blog 'Looking after your bladder & kindeys.'.
  • DensiMAX™ tablets

    R211,99 incl VAT
    FLORA FORCE® DensiMAX® tablets is a multi-mineral supplement with calcium and Vitamin D; supports healthy bones and teeth and plays a role in maintaining good health. Calcium intake, when combined with sufficient Vitamin D, a healthy diet and regular exercise, may reduce the risk of developing osteoporosis. Free from sugar and lactose. If you are pregnant or breastfeeding, please consult your pharmacist or registered healthcare practitioner for advice before taking DensiMAX®tablets.

    PATIENT INFORMATION LEAFLET

    Information for the Patient about DensiMAX® Tablets

    Western herbal medicine This medicine has not been evaluated by the Medicines Control Council. This medicine is not intended to diagnose, treat, cure or prevent any disease. SCHEDULING STATUS: Not Scheduled PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: DensiMAX® tablets.
    Read all of this leaflet carefully because it contains important information for you. DensiMAX® tablets are available without a doctor’s prescription, for you to treat a mild illness. Nevertheless, you still need to use DensiMAX® tablets carefully to get the best results from it.
    • Keep this leaflet. You may need to read it again.
    • Do not share DensiMAX® with any other person.
    • Ask your pharmacist if you need more information or advice.
    • You must see a registered healthcare practitioner if your symptoms worsen or do not improve.
    WHAT DensiMAX® TABLETS CONTAIN: Each DensiMAX® tablet contains:
    ACTIVE INGREDIENT QUANTITY DAILY DOSAGE RDA
    Calcium (from Aquamin™ *Lithothamnium calcareum) 450 mg 900 mg 90%
    Magnesium (from Aquamin™ *Lithothamnium calcareum) 31 mg 62 mg 19%
    Vitamin D3 (Cholecalciferol) 240 IU 480 IU 80%
    Trace minerals (from Aquamin™ *Lithothamnium calcareum) 72 Trace minerals including Boron, Chloride, Iron, Phosphorus, Potassium, Selenium, Sodium, Zinc 444 mg 888 mg
    Inactive ingredients: gum acacia, sodium carboxy-methyl cellulose, and magnesium stearate. DensiMAX® tablets are free from sugar and lactose.
    WHAT DensiMAX® TABLETS ARE USED FOR: DensiMAX® tablets is a multi-mineral supplement that supports healthy bones and teeth and is a factor in the maintenance of good health. Calcium intake, when combined with sufficient Vitamin D, a healthy diet, and regular exercise, may reduce the risk of developing osteoporosis. BEFORE YOU TAKE DensiMAX® TABLETS: Do NOT take DensiMAX® tablets:
    • If you are allergic to any of the ingredients in DensiMAX® tablets
    • If you have abnormally high levels of calcium in the blood and/or excessive loss of calcium in the urine (see “Take special care with DensiMAX® tablets”).
    • If you high or low levels of phosphate in the blood (see “Take special care with DensiMAX® tablets”).
    • Surgery (see “Take special care with DensiMAX® tablets”).
    Take special care with DensiMAX® tablets: Please discuss the use of DensiMAX® tablets with your pharmacist or registered healthcare practitioner if you:
    • Suffer from have abnormally high levels of calcium in the blood and/or excessive loss of calcium in the urine. Conditions that lead to abnormally high levels of calcium in the blood include para-thyroid gland disorders, sarcoidosis, poor kidney function and bone cancer. Conditions that lead to abnormally low levels of calcium in the blood are kidney stones and kidney failure (see “Do NOT take DensiMAX® tablets”).
    • Suffer from high or low levels of phosphate in the blood. You may have to arrange increased monitoring of your phosphate levels when starting or stopping treatment with DensiMAX® tablets (see “Do NOT take DensiMAX® tablets”).
    • Suffer from low levels of stomach acid. People with low levels of gastric acid absorb less calcium if it is taken on an empty stomach. However, low acid levels in the stomach do not reduce calcium absorption if calcium is taken with food (see “Do NOT take DensiMAX® tablets”).
    • Are a smoker. Smokers absorb less calcium from the stomach. The dose of DensiMAX® tablets may need to be adjusted if you smoke.
    • Are undergoing surgery, discontinue use at least 2 weeks prior to the procedure (see “Do NOT take DensiMAX® tablets”).
    • Take warfarin or other blood thinning medicines. You may have to arrange increased monitoring or your INR (International Normalised Ratio) levels when starting or stopping treatment with DensiMAX® tablets (see “Taking other medicines with DensiMAX® tablets”).
    The use of DensiMAX® tablets in children and adolescents under 18 years of age is not recommended due to lack of adequate data (see “HOW TO TAKE DensiMAX® TABLETS”). Taking DensiMAX® tablets with food and drink: DensiMAX® tablets should be taken with meals with water. Pregnancy and breastfeeding: Use DensiMAX® tablets under supervision of a pharmacist or registered healthcare practitioner.
    If you are pregnant or breastfeeding your baby, please consult your doctor, pharmacist or registered healthcare practitioner for advice before taking DensiMAX® tablets.
    Driving and using machinery: No studies on the effect on the ability to drive and use machinery have been performed. It is unlikely that DensiMAX® tablets will impair your ability to drive or use machines. However, please exercise care when driving or operating machinery until you know how DensiMAX® tablets affects you. Important information about some of the ingredients of DensiMAX® tablets: DensiMAX® tablets are sugar and lactose free. Taking other medicines with DensiMAX® tablets:
    Always tell your pharmacist or registered healthcare practitioner if you are taking any other medicine. (this includes complementary or traditional medicines).
    Please discuss the use of the following medicines in combination with DensiMAX® tablets with your pharmacist or registered healthcare practitioner:
    • Calcipotriene, a medicine similar to vitamin D, for the treatment of psoriasis.
    • Diltiazem for the treatment of high blood pressure, angina and heart rhythm disorders.
    • Lithium for the treatment of bipolar disorder.
    • Potassium sparing diuretics for the treatment of hypertension and management of congestive heart failure.
    • Skeletal muscle relaxants used to alleviate muscle spasms, pain, and hyperreflexia.
    The dose of the above medications may need to be adjusted when taken with DensiMAX® tablets. Also, discuss the use of the following medicines in combination with DensiMAX® tablets with your pharmacist or registered healthcare practitioner:
    • Raltegravir (an anti-retroviral medication). DensiMAX® tablets may decrease its levels.
    • Thiazide diuretics. DensiMAX® tablets could increase calcium levels in the blood. Monitor you calcium and parathyroid function regularly if you are using DensiMAX® tablets and thiazide diuretics in combination.
    • Antacids as DensiMAX® tablets may reduce the levels of magnesium.
    • Anti-diabetic medicines. DensiMAX® tablets may increase its effects. Monitor you blood sugar levels regularly if you are using DensiMAX® tablets and anti-diabetic medicines in combination.
    • Warfarin or other blood thinning medicines. DensiMAX® tablets may potentially increase the effect of blood thinning medicines (see “Take special care with DensiMAX® tablets”).
    • Biphosphonates as DensiMAX® tablets can influence the absorption and effectiveness of these medicines (see “HOW TO TAKE DensiMAX® TABLETS”).
    • Levothyroxine, taken for hypothyroidism, as DensiMAX® tablets may decrease its absorption (see “HOW TO TAKE DensiMAX® TABLETS”).
    • Integrase inhibitors, used to treat HIV, as DensiMAX® tablets may decrease the levels of this medication (see “HOW TO TAKE DensiMAX® TABLETS”).
    • Tetracylcine and quinolone antibiotics as DensiMAX® tablets decreases the levels of this medication (see “HOW TO TAKE DensiMAX® TABLETS”).
    • Sotalol as DensiMAX® tablets decreases the levels of this medication (see “HOW TO TAKE DensiMAX® TABLETS”).
    • Gabapectin as DensiMAX® tablets decreases levels of this medication (see “HOW TO TAKE DensiMAX® TABLETS”).
    HOW TO TAKE DensiMAX® TABLETS: Do not share medicines prescribed to you with any other person. Always take DensiMAX® tablets exactly as directed. You should check with your pharmacist or registered healthcare practitioner if you are unsure. DO NOT EXCEED THE RECOMMENDED DAILY DOSAGE. Adults (18 years and older): Take 1 tablet twice daily with meals or as directed by your pharmacist or registered healthcare practitioner. Children (under 18 years of age): Not recommended for use (see “Take special care with DensiMAX® tablets”). Bisphosphonates must be taken 30 min prior or at a different time of the day. Levothyroxin must be taken at least 4 hours apart from DensiMAX® tablets. Integrase inhibitors, tetracycline and quinoline antibiotics, sotalol and gabapectin must be taken at least 2 hours before, or 4-6 hours after DensiMAX® tablets (see “Taking other medicines with DensiMAX® tablets”). DensiMAX® tablets may be taken for a period of up to 12 weeks followed by an interval of 1 week after which the next 12-week cycle can commence. However, should you experience any adverse effects or any of the side effects indicated below please consult your pharmacist or registered healthcare practitioner. If you take more DensiMAX® tablets than you should: If you take more DensiMAX® tablets than you should, you may experience thirst, drowsiness, confusion, weakness, difficulty breathing, chest pain and unconsciousness. In the event of over dosage, consult your pharmacist or registered healthcare practitioner. If neither is available, contact the nearest hospital or poison control centre. If you forget to take DensiMAX® tablets: Always take DensiMAX® tablets as directed. If you miss a dose, take it as soon as you remember. If you do not remember the missed dose till the next dose is due, skip the missed dose and go back to your regular dosing schedule of one tablet twice daily. Do not take a double dose to make up for forgotten individual doses. POSSIBLE SIDE-EFFECTS: DensiMAX® tablets may have side-effects. Not all side-effects reported for DensiMAX® tablets. Should your general health worsen or if you experience any untoward effects while taking DensiMAX® tablets, please consult your pharmacist or registered healthcare practitioner for advice. Serious side-effects that you (or a family member if you are unable to) should report to your pharmacist or registered healthcare practitioner immediately include:
    • An allergic reaction which may present with shortness of breath, difficulty breathing, wheezing, hives, or itching, swelling of the face, tongue or whole body.
    • Chest pain, nausea, vomiting, constipation, abdominal pain, increased thirst & urination, fatigue, muscle weakness & pain, confusion, disorientation, difficulty talking, headaches, depression and poor appetite.
    • Blood in urine, fever and chills, sever stomach or back pain.
    Side-effects that you should report to your pharmacist or registered healthcare practitioner as soon as possible:
    • Less or more urine than is normal for you.
    • Swollen face, feet and ankles.
    • Breath odour.
    Side-effects that you should report to your pharmacist or registered healthcare practitioner if they continue or become bothersome include:
    • Gastrointestinal disturbances, such as:
      • Stomach discomfort, indigestion, diarrhoea, constipation, belching, acid reflux & heartburn, flatulence.
    If you notice any side-effects not mentioned in this leaflet, please inform your pharmacist or registered healthcare practitioner. STORING AND DISPOSING OF DensiMAX® tablets: Store at or below 25ºC in a dry place. Protect from light / moisture. Do not take the capsules after the expiry date stated on the packaging material. Return all unused capsules to your pharmacist. Do not dispose of unused capsules in drains or sewerage systems (e.g. toilets). STORE ALL MEDICINE OUT OF THE REACH OF CHILDREN. PRESENTATION OF DensiMAX® tablets: 60 Tablets packed in a 125ml amber glass bottle with a seal and mustard gold screw cap in a product box with a package insert. IDENTIFICATION OF DensiMAX® tablets: 23 mm oblong off-white tablet. REGISTRATION NUMBER/REFERENCE NUMBER: To be allocated. NAME AND BUSINESS ADDRESS OF THE HOLDER OF THE CERTIFICATE OF REGISTRATION: Flora Force Heath Products (Pty) Ltd. Unit 3 Regent Park Bell Crescent Westlake Cape Town South Africa DATE OF PUBLICATION: 07/11/2017 *Aquamin™ is a registered trade mark of Marigot Ltd. Ireland
    DensiMAX® Tablets Health Supplement This medicine has not been evaluated by the Medicines Control Council. This medicine is not intended to diagnose, treat, cure or prevent any disease. SCHEDULING STATUS: Not Scheduled PROPRIETARY NAME (AND DOSAGE FORM): DensiMAX® Tablets COMPOSITION: Each DensiMAX® tablet contains:
    ACTIVE INGREDIENT QUANTITY DAILY DOSAGE RDA
    Calcium (from Aquamin™ *Lithothamnium calcareum) 450 mg 900 mg 90%
    Magnesium (from Aquamin™ *Lithothamnium calcareum) 31 mg 62 mg 19%
    Vitamin D3 (Cholecalciferol) 240 IU 480 IU 80%
    Trace minerals (from Aquamin™ *Lithothamnium calcareum) 72 Trace mineral including Boron, Chloride, Iron, Phosphorus, Potassium, Selenium, Sodium, Zinc 444 mg 888 mg
    Inactive ingredients: gum acacia, sodium carboxy-methyl cellulose, magnesium stearate. DensiMAX® tablets are free from sugar and lactose. PHARMACOLOGICAL CLASSIFICATION: D 22.2 Vitamins - Other. PHARMACOLOGICAL ACTION: Pharmacodynamic properties: Aquamin is a marine-sourced multi-mineral, which is derived from the cytoskeleton of the red algae Lithothamnion calcareum. Over the course of the aquatic plant's life, minerals are accumulated from the seawater, and stored as carbonate salts in the plant. Aquamin™ has the ability to improve osteoblast bone cell mineralisation and promote early bone mineral build-up. By re-mineralizing the cells, the number of osteoblasts are increased. Osteoblasts are responsible for new bone formation. Aquamins' osteogenic (bone tissue formation) response is improved by the addition of Vitamin D3.

    INDICATIONS: DensiMAX® is a multi-mineral supplement that supports healthy bones and teeth and is a factor in the maintenance of good health. Calcium intake, when combined with sufficient Vitamin D, a healthy diet, and regular exercise, may reduce the risk of developing osteoporosis. CONTRA-INDICATIONS: DensiMAX® tablets are contra-indicated in patients with:
    • A hypersensitivity to calcium, vitamin D or to one of the other ingredients in DensiMAX® tablets including seafood, seaweeds and specific trace minerals.
    • Hyper-calcaemia and/or hyper-calciuria (see “WARNINGS AND SPECIAL PRECAUTIONS”).
    • Hyper-phosphatemia and/or hypo-phosphataemia (see “WARNINGS AND SPECIAL PRECAUTIONS”).
    • Achlorhydria (see “WARNING AND SPECIAL PRECAUTIONS”).
    • Smoking (see “WARNING AND SPECIAL PRECAUTIONS”).
    • Surgery (see “WARNINGS AND SPECIAL PRECUATIONS”).
    WARNINGS AND SPECIAL PRECAUTIONS: DensiMAX® tablets should be used with care in patients with hyper-calcaemia and/or hyper-calciuria (see “CONTRA-INDICATIONS”).  DensiMAX® tablets should be used with care in conditions that could lead to increased calcium absorption and hypercalcaemia such as, hyper-parathyroidism, renal insufficiency, sarcoidosis, bone tumour and myeloma (see “CONTRA-INDICATIONS”). DensiMAX™ tablets should be used with care in conditions that could lead to decreased renal calcium reabsorption and hyper-calciuria such as kidney stones, nephron-calcinosis and kidney failure (see “CONTRA-INDICATIONS”). DensiMAX® tablets should be used cautiously in patients with hyper-phosphatemia and/or hypo-phosphatemia.  These patients should have increased monitoring of their serum phosphate levels (see “CONTRA-INDICATIONS”). DensiMAX® tablets should be used with care in patients with achlorhydria as these patients have lower calcium absorption in a fasting state compared to patients with normal gastric acid secretion. When calcium is taken with a meal, reduced gastric acidity does not significantly impair absorption.  Patients with achlorhydria should therefore take calcium with a meal (see “CONTRA-INDICATIONS”). DensiMAX® tablets should be used with care in patients that smoke.  Cigarette smoking decreases intestinal calcium absorption (see “CONTRA-INDICATIONS”). DensiMAX® tablets should be used with care in patients undergoing surgery.  Patients should discontinue use at least 2 weeks before elective surgical procedures (see “CONTRA-INDICATIONS”). When starting, or stopping treatment with magnesium containing products, including DensiMAX® tablets, patients taking warfarin (or other coumarin anti-coagulants) should have increased monitoring of their INR (International Normalised Ratio) levels (see “INTERACTIONS”). The use of DensiMAX® tablets in children and adolescents under 18 years of age is not recommended due to lack of adequate data (see “DOSAGE AND DIRECTIONS FOR USE”). Effects on the ability to drive or use machinery: No studies on the effect of DensiMAX® tablets on the ability to drive or operate machines have been performed.  It is unlikely that DensiMAX® tablets will affect the ability to drive or operate machines. INTERACTIONS: The herbs in DensiMAX® tablets may interact with the following medicines:
    • Calcipotriene (Vitamin D analogue): may cause increased calcium absorption.
    • Diltiazem: calcium can decrease effectiveness.
    • Lithium: long-term lithium use may cause hypercalcemia.
    • Potassium sparing diuretics: may increase levels of magnesium.
    • Skeletal muscle relaxants: magnesium may increase levels.
    There is some evidence that taking calcium and vitamin D with the anti-retroviral (ARV) drug, raltegravir, possibly reduces its levels.  Until more is known, use with caution when taking raltegravir along with repeated doses of calcium. The use of thiazide diuretics with calcium, as in DensiMAX® tablets could increase the risk of hypercalcemia, metabolic alkalosis and renal failure.  Patients taking thiazide diuretics should consult their healthcare practitioner about appropriate calcium doses and to have their serum calcium levels and/or parathyroid function monitored regularly.  These diuretics include chlorothiazide, hydrochlorothiazide, indapamide, metolazone and chlorthalidone. The use of antacids with magnesium, as in DensiMAX® tablets, may reduce the levels of magnesium.  Patients taking antacids should consult their healthcare practitioner and may need to adjust their dose of magnesium. Magnesium, as in DensiMAX® tablets, may enhance the blood glucose lowering effects of anti-diabetic medicines.  Patients on anti-diabetic medicines should monitor their glucose levels closely when taking DensiMAX® tablets. Magnesium, as in DensiMAX® tablets, may increase the effect of oral anti-coagulants and anti-platelet drugs (e.g. warfarin, aspirin, clopidogrel, dalteparin, enoxaparin, heparin) when taken concomitantly.  Patients taking anti-coagulants or anti-platelet medicines should have their INR levels monitored more frequently when taking DensiMAX® tablets (see “WARNINGS AND SPECIAL PRECAUTIONS”). Calcium and magnesium, as in DensiMAX® tablets, may decrease absorption of bisphosphonates, taken to prevent loss of bone mass, when taken concomitantly.  Advise patients to take bisphosphonates 30 minutes before DensiMAX® tablets, but preferably at a different time of day.  Some of these medications include alendronate, etidronate, ibandronate, risedronate and tiludronate (see “DOSAGE AND DIRECTIONS FOR USE”). Calcium carbonate, as in DensiMAX® tablets, may reduce the effectiveness of levothyroxine in patients with hypothyroid.  Advise patients to take levothyroxine and calcium supplement at least 4 hours apart (see “DOSAGE AND DIRECTIONS FOR USE”). Advise patients to separate doses of the below medicines by at least 2 hours before, or 4-6 hours after DensiMAX® tablets (see “DOSAGE AND DIRECTIONS FOR USE”). There is evidence that taking calcium, as in DensiMAX® tablets, with integrase inhibitors, used to treat HIV, may reduce levels of the medication.  These medications include dolutegravir and elvitegravir. Calcium and magnesium, as in DensiMAX® tablets, may decrease the absorption of tetracycline and quinolone antibiotics.  Tetracyclines include demeclocycline, doxyclycline and minocycline.  Quinolones include, ciprofloxacin, levofloxacin, ofloxacin, moxifloxacin, gatifloxacin, Gemifloxacin and others. Calcium, as in DensiMAX® tablets, may decrease the absorption of sotalol. Magnesium, as in DensiMAX® tablets, may decrease levels of gabapentin. PREGNANCY AND LACTATION: Use DensiMAX® tablets under supervision of a healthcare practitioner. DOSAGE AND DIRECTIONS FOR USE: The recommended daily dose should not be exceeded. Adults (18 years and older): Take 1 tablet twice daily with meals or as prescribed. Children (under 18 years of age): Not recommended for use (see “WARNINGS AND SPECIAL PRECAUTIONS”). Bisphosphonates must be taken 30 min prior or at a different time of the day.  Levothyroxin must be taken at least 4 hours apart from DensiMAX® tablets.  Integrase inhibitors, tetracycline and quinoline antibiotics, sotalol and gabapectin must be taken at least 2 hours before, or 4-6 hours after DensiMAX® tablets (see “INTERACTIONS”). SIDE-EFFECS: The following side-effects may occur with the use of DensiMAX® tablets. Endocrine disorders: Frequency unknown:         Hypercalcemia, Milk-alkali syndrome, hyper-magnesemia. Vascular disorders: Frequency unknown:         Myocardial infarct, atherosclerosis. Respiratory, thoracic and mediastinal disorders: Frequency unknown: Respiratory depression Gastrointestinal disorders: Frequency unknown:         Gastro-intestinal irritation, nausea, vomiting, diarrhoea, belching, flatulence and acid reflux. Renal and urinary disorders: Frequency unknown:         Nephro-calcinosis and renal insufficiency. KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENTS: The following symptoms may be experienced in the event of an overdose: Thirst, hypotension, drowsiness, confusion, loss of tendon reflexes, muscle weakness, respiratory depression, cardiac arrhythmias, coma and cardiac arrest. Contact a poison control centre in area. IDENTIFICATION: 23 mm oblong off-white tablet. PRESENTATION: 60 Tablets packed in a 125ml amber glass bottle with a seal and mustard gold screw cap in a product box and package insert. STORAGE INSTRUCTIONS: Store at or below 25 ºC in a dry place. Protect from light. KEEP OUT OF REACH OF CHILDREN. REGISTRATION NUMBER: To be allocated. NAME AND BUSINESS ADDRESS OF THE HOLDER OF THE CERTIFICATE OF REGISTRATION: Flora Force Heath Products (Pty) Ltd. Unit 3 Regent Park Bell Crescent Westlake Cape Town DATE OF PUBLICATION: To be allocated. *Aquamin™ is a registered trade mark of Marigot Ltd. Ireland

    Herb Library

    Explore our Herb Library for additional information on traditional uses of herbs.

    Related blog articles

    Read more about bone health in our blog ‘Bone health and the calcium connection’.
  • Devils claw tablets

    R105,89 incl VAT
    Treats degenerative musculo-skeletal and joint conditions such as arthritis, osteoporosis, rheumatism, and gout. Anti-inflammatory, reducing pain and swelling associated with arthritis and rheumatism; improves joint mobility. 500mg, 60 tablets.
  • Green barley grass is harvested from young barley plants no taller than 25cm. By using these young plants, we ensure that optimal minerals and vitamins are retained in the plant’s leaves. Of particular note are the high levels of chlorophyll present in green barley (chlorophyll is the plant equivalent of haemoglobin in humans). There are some differences between barley kernels (as cooked in cereal or other dishes) and green barley grass, the most notable of which is the presence of chlorophyll in the latter.